# Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

> **NCT04053322** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 172 (actual)

## Conditions studied

- ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
- a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Olaparib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT04053322
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-26
- **Primary completion:** 2023-11-15
- **Final completion:** 2027-08
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04053322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04053322, "Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04053322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*